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Gliomas, which are brain tumors that arise from glial cells, are some of
the most aggressive and lethal types of tumors. These brain tumors are
difficult to treat because not enough information regarding the mutations
present in these tumors exists. This project studies effects of a p53
mutation on Drosophila glioma progression and then will test to see if this
results in resistance to current chemotherapy. Drosophila are used as
model organisms to mimic these processes. The current genetic crosses
that have been created will be studied, and an effective p53 knockdown
will be made. In essence, this will effectively mimic a human brain tumor
so the treatments tested and the data collected from this model can be
applied to the current understanding of human gliomas. In addition to
studying just the p53 mutation, PI3K and oncogenic Ras signaling will be
coactivated. This will lead to an even more accurate glioma model
because multiple mutations, such as the ones added are present in
human tumors as well. These genetic crosses will be treated with
Tyrosine Kinase Inhibitors, which are currently used to treat brain cancer
patients in order to find out whether or not this mutation plays a role in
resistance to current therapy. The main goal of this endeavor is to
investigate the numerous defects occurring at the cellular and
biochemical level in gliomas, which will give insight into why these types
of tumors are so difficult to treat. Data gathered from this project will lead
to further inquiry into the role of p53 mutations in gliomas and hopefully,
to better outcomes for those affected by this type of cancer. Here, we
present the data gathered from this project thus far.

The goal of this project is to investigate why some gliomas do not
respond well to chemotherapy. One approach to this is to compare the
response of two genetically different glioma to a slew of drugs known to
partially affect or weakly inhibit tumor growth. The p53 mutation is thought
to play a role in this resistance. This specific mutation can be modeled in
Drosophila melanogaster, both independently and in conjunction with
other commonly occurring mutations in glioma.
The p53 gene acts as a tumor suppressor in addition to its numerous
other functions concerning the cell cycle. The E2F family of genes, which
will also be tested along with p53, help control the cell cycle. Mutations in
both of these genes are known to occur in patients with gliomas, but their
role in glioma progression and response to therapies is not well
understood.
If more information regarding the exact mutations present in gliomas
existed, more targeted therapies could be used to act on the pathways
known to contribute to tumor development and chemotherapy resistance.
This project aims to explore these mutations in an effort to bridge this gap
in information, so therapies can efficiently destroy the tumor without
causing damage to healthy tissues. We present the preliminary data
necessary to create the various glioma model here
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The larvae produced from the UASp53
H159N; repoGal4 cross had
decreased glia in the optic lobes and they were clustered in
the ventral nerve cord.
• The larvae produced from the UASE2FRNAi; repoGal4 cross
had glia clustered in the ventral nerve cord as well.
• Some of the larvae from the UASE2FRNAi; repoGal4 were
deformed and had their ventral nerve cord curved upward,
attached to an optic lobe.
• A majority of the larvae hatched. This viability shows that
further crosses made with this offspring are possible.
• This data shows promise for continued genetic crosses to
eventually create a p53 knockdown which exhibits glioma.
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1. Create an effective glioma model expressing a p53 mutation
2. Combine the p53 mutation with coactivation of Ras PI3 Kinase
along with additional mutations that are present in human gliomas.
3. Treat the p53, Ras PI3 Kinase gliomas with Tyrosine Kinase
Inhibitors in order to test for therapy resistance.
4. Use Western blotting to determine the mechanism of the mode of
action.
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